Filtered By:
Condition: Bleeding
Countries: USA Health
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 173 results found since Jan 2013.
Consensus statement: Hemostasis trial outcomes in cardiac surgery/mechanical support
CONCLUSIONS: The proposed composite risk scores could impact design of upcoming clinical trials and enable comparability of future investigations. Harmonizing and disseminating global consensus definitions and management guidelines can also reduce patient heterogeneity that would confound standardized primary outcomes in future research.PMID:34826386 | DOI:10.1016/j.athoracsur.2021.09.080
Source: The Annals of Thoracic Surgery - November 26, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Jerrold H Levy David Faraoni Christopher S Almond Lisa Baumann-Kreuziger Melania M Bembea Jean M Connors Heidi J Dalton Ryan Davies Larry J Dumont Massimo Griselli Keyvan Karkouti M Patricia Massicotte Jun Teruya Ravi R Thiagarajan Philip C Spinella Marie Source Type: research
Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: Readmissions after LVAD
Ann Thorac Surg. 2022 Jan 7:S0003-4975(22)00007-8. doi: 10.1016/j.athoracsur.2021.12.011. Online ahead of print.ABSTRACTThe twelfth annual report from the Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) highlights outcomes for 26,688 continuous-flow LVAD patients over the past decade (2011-2020). In 2020, we observed the largest drop in yearly LVAD implant volumes since the registry's inception, which reflects the effects of the COVID-19 pandemic on cardiac surgical volumes in the United States. The 2018 heart transplant allocation policy change in the U.S. ...
Source: The Annals of Thoracic Surgery - January 10, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Palak Shah Melana Yuzefpolskaya Gavin W Hickey Khadijah Breathett Omar Wever-Pinzon Van Khue-Ton William Hiesinger Devin Koehl James K Kirklin Ryan S Cantor Jeffrey P Jacobs Robert H Habib Francis D Pagani Daniel J Goldstein Source Type: research
Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
CONCLUSION: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.PMID:35726631 | DOI:10.1161/CIRCULATIONAHA.122.058575
Source: Circulation - June 21, 2022 Category: Cardiology Authors: Derek S Chew Yanhong Li Patricia A Cowper Kevin J Anstrom Jonathan P Piccini Jeanne E Poole Melanie R Daniels Kristi H Monahan Linda Davidson-Ray Tristram D Bahnson Hussein R Al-Khalidi Kerry L Lee Douglas L Packer Daniel B Mark CABANA Investigators Source Type: research
Influence of the Danish Co-morbidity Index Score on the Treatment and Outcomes of 2.5 Million Patients Admitted With Acute Myocardial Infarction in the United States
This study aimed to determine the association between the Danish Co-morbidity Index for Acute Myocardial Infarction (DANCAMI) and restricted DANCAMI (rDANCAMI) scores and clinical outcomes in patients hospitalized with AMI. Using the National Inpatient Sample, all AMI hospitalizations were stratified into four groups based on their DANCAMI and rDANCAMI score (0; 1 to 3; 4 to 5; ≥6). The primary outcome was all-cause mortality, whereas secondary outcomes were major adverse cardiovascular/cerebrovascular events, major bleeding, ischemic stroke, and receipt of coronary angiography or percutaneous coronary intervention.
Source: The American Journal of Cardiology - July 14, 2022 Category: Cardiology Authors: Balamrit Singh Sokhal, Andrija Mateti ć, Abhishek, Philip Freeman, Jan Walter Dhillon Shanmuganathan, Mohamed O. Mohamed, Christian Mallen, Mamas A. Mamas Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
